New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
.
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2016-09-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Online Access: | https://www.rpcardio.com/jour/article/view/1319 |
_version_ | 1797659285438595072 |
---|---|
author | Article Editorial |
author_facet | Article Editorial |
author_sort | Article Editorial |
collection | DOAJ |
description | . |
first_indexed | 2024-03-11T18:12:48Z |
format | Article |
id | doaj.art-fcfd611199814f7c909a4a9aaf338e89 |
institution | Directory Open Access Journal |
issn | 1819-6446 2225-3653 |
language | English |
last_indexed | 2024-03-11T18:12:48Z |
publishDate | 2016-09-01 |
publisher | Столичная издательская компания |
record_format | Article |
series | Рациональная фармакотерапия в кардиологии |
spelling | doaj.art-fcfd611199814f7c909a4a9aaf338e892023-10-16T11:32:10ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-09-011244874881252New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)Article Editorial.https://www.rpcardio.com/jour/article/view/1319 |
spellingShingle | Article Editorial New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Рациональная фармакотерапия в кардиологии |
title | New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) |
title_full | New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) |
title_fullStr | New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) |
title_full_unstemmed | New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) |
title_short | New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) |
title_sort | new data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug xarelto r in patients with atrial fibrillation press release of the company bayer |
url | https://www.rpcardio.com/jour/article/view/1319 |
work_keys_str_mv | AT articleeditorial newdatafromclinicalpracticeagainconfirmedthehighefficacyandafavorablesafetyprofileofthedrugxareltoinpatientswithatrialfibrillationpressreleaseofthecompanybayer |